votrient pazopanib hydrochloride tablet film coated
glaxosmithkline llc - pazopanib hydrochloride (unii: 33y9anm545) (pazopanib - unii:7rn5dr86ck) - pazopanib 200 mg
pazopanib pharmacare 200 mg film-coated tablets
pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - pazopanib 200 mg - antineoplastic agents
pazopanib pharmacare 400 mg film-coated tablets
pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - pazopanib 400 mg - antineoplastic agents
votrient pazopanib 200 mg tablet bottle
novartis pharmaceuticals australia pty ltd - pazopanib hydrochloride, quantity: 216.7 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc). votrient is indicated for the treatment of patients with advanced (unresectable and/or metastatic) soft tissue sarcoma (sts) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment. the phase iii trial population excluded patients with gastrointestinal stromal tumour (gist) or adipocytic soft tissue sarcoma.
votrient pazopanib 400 mg tablet bottle
novartis pharmaceuticals australia pty ltd - pazopanib hydrochloride, quantity: 433.4 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc). votrient is indicated for the treatment of patients with advanced (unresectable and/or metastatic) soft tissue sarcoma (sts) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment. the phase iii trial population excluded patients with gastrointestinal stromal tumour (gist) or adipocytic soft tissue sarcoma.
votrient tablet 200 mg
novartis (singapore) pte ltd - pazopanib hydrochloride 216.7 mg eqv pazopanib - tablet, film coated - 200 mg - pazopanib hydrochloride 216.7 mg eqv pazopanib 200 mg
votrient tablet 400 mg
novartis (singapore) pte ltd - pazopanib hydrochloride 433.4 mg eqv pazopanib - tablet, film coated - 400 mg - pazopanib hydrochloride 433.4 mg eqv pazopanib 400 mg
votrient tablet
novartis pharmaceuticals canada inc - pazopanib (pazopanib hydrochloride) - tablet - 400mg - pazopanib (pazopanib hydrochloride) 400mg - antineoplastic agents
pazopanib eg 200 mg film-coat. tabl.
eg sa-nv - pazopanib hydrochloride 216,7 mg - eq. pazopanib 200 mg - film-coated tablet - pazopanib
pazopanib eg 400 mg film-coat. tabl.
eg sa-nv - pazopanib hydrochloride 433,4 mg - eq. pazopanib 400 mg - film-coated tablet - pazopanib